Cargando…

Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need

SIMPLE SUMMARY: Among all types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is the most common type and has an extremely low survival rate. Early detection at an early stage, when surgical removal is still available, is crucial to minimize the death toll of the individuals who are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liou, Geou-Yarh, Byrd, Crystal J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177101/ https://www.ncbi.nlm.nih.gov/pubmed/37173913 http://dx.doi.org/10.3390/cancers15092446

Ejemplares similares

Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers
por: Liou, Geou-Yarh
Publicado: (2017)

Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development
por: Messex, Justin K., et al.
Publicado: (2020)

Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer
por: Liou, Geou-Yarh, et al.
Publicado: (2015)

Population Equation: Balancing What We Need With What We Have
por: Dahl, Richard
Publicado: (2005)

Downregulation of TRAF2 Mediates NIK-Induced Pancreatic Cancer Cell Proliferation and Tumorigenicity
por: Döppler, Heike, et al.
Publicado: (2013)

Macrophages Cytokine Spp1 Increases Growth of Prostate Intraepithelial Neoplasia to Promote Prostate Tumor Progression
por: Messex, Justin K., et al.
Publicado: (2022)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Neurophysiology of the Developing Cerebral Cortex: What We Have Learned and What We Need to Know
por: Luhmann, Heiko J.
Publicado: (2022)

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
por: Delire, Bénédicte, et al.
Publicado: (2015)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

What have we learned and what do we still need to learn about nPDF?
por: Paakkinen, Petja
Publicado: (2021)

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need
por: Bidell, Monique R., et al.
Publicado: (2016)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023)

MicroRNAs and cancer: what we know and what we still have to learn
por: Calin, George A
Publicado: (2009)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Epigenetics in Schistosomes: What We Know and What We Need Know
por: Liu, Weiwei
Publicado: (2016)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020)

Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis
por: Messex, Justin K., et al.
Publicado: (2023)

Generation of Hydrogen Peroxide and Downstream Protein Kinase D1 Signaling Is a Common Feature of Inducers of Pancreatic Acinar-to-Ductal Metaplasia
por: Döppler, Heike R., et al.
Publicado: (2022)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Lipoabdominoplasty: What We Have Implemented and What We Have Modified over 26 Years
por: Cárdenas-Camarena, Lázaro, et al.
Publicado: (2023)

Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know
por: Bogers, Sophie Helen
Publicado: (2018)

A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need
por: Ermakov, Sergey, et al.
Publicado: (2019)

First-Episode Psychosis care in Central Europe: What we have learned and what we still need to do
por: Réthelyi, J.
Publicado: (2022)

Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option
por: Messex, Justin K., et al.
Publicado: (2021)

Asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

What We Most Need
por: De Camp, G. W.
Publicado: (1866)

Macrophage Cytokines Enhance Cell Proliferation of Normal Prostate Epithelial Cells through Activation of ERK and Akt
por: Dang, Tu, et al.
Publicado: (2018)

Pregnant adolescents living with HIV: what we know, what we need to know, where we need to go
por: Callahan, Tegan, et al.
Publicado: (2017)

Nephrotoxicity testing in vitro--what we know and what we need to know.
por: Pfaller, W, et al.
Publicado: (1998)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Membrane fission by dynamin: what we know and what we need to know
por: Antonny, Bruno, et al.
Publicado: (2016)

Microplastics in freshwater ecosystems: what we know and what we need to know
por: Wagner, Martin, et al.
Publicado: (2014)

Peri-implant disease: what we know and what we need to know
por: Valente, Nicola Alberto, et al.
Publicado: (2016)

Pneumonia in Bhutanese children: what we know, and what we need to know
por: Jullien, Sophie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p56epe02j3os3os27c9s5bqt1i